Pluristem
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more
Pluristem (PSTI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2022: -0.235x
Based on the latest financial reports, Pluristem (PSTI) has a cash flow conversion efficiency ratio of -0.235x as of March 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-9.42 Million) by net assets (ILA40.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pluristem - Cash Flow Conversion Efficiency Trend (2014–2021)
This chart illustrates how Pluristem's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pluristem Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluristem ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grade Upon Technology Corp
TWO:6739
|
N/A |
|
WEIR GROUP
BE:42W
|
N/A |
|
Grayscale Digital Large Cap Fund Ll
OTCQX:GDLC
|
-0.199x |
|
Constellation Acquisition Corp I
OTCQB:CSTUF
|
0.004x |
|
TRAFALGA PPTY GR.LS-001
F:8Q5
|
N/A |
|
Michichi Capital Corp.
V:MCCP-P
|
-0.001x |
|
Lombard et Medot SA
PA:MLCAC
|
N/A |
|
Infinico Metals Corp.
V:INFM
|
1.247x |
Annual Cash Flow Conversion Efficiency for Pluristem (2014–2021)
The table below shows the annual cash flow conversion efficiency of Pluristem from 2014 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-06-30 | ILA57.15 Million | ILA-30.91 Million | -0.541x | -15.07% |
| 2020-06-30 | ILA56.10 Million | ILA-26.37 Million | -0.470x | +65.18% |
| 2019-06-30 | ILA21.82 Million | ILA-29.45 Million | -1.350x | -79.97% |
| 2018-06-30 | ILA28.51 Million | ILA-21.38 Million | -0.750x | -4.98% |
| 2017-06-30 | ILA30.25 Million | ILA-21.61 Million | -0.714x | -47.17% |
| 2016-06-30 | ILA38.16 Million | ILA-18.52 Million | -0.485x | -36.98% |
| 2015-06-30 | ILA58.14 Million | ILA-20.61 Million | -0.354x | -15.14% |
| 2014-06-30 | ILA62.12 Million | ILA-19.12 Million | -0.308x | -- |